Cash-Pay Growth Hormone Therapy for Kids: What Families Should Expect

Many families first learn about growth hormone treatment after a pediatric growth evaluation identifies a condition affecting growth. While some children qualify for insurance coverage, others do not.

This often leads parents to research cash-pay growth hormone therapy for kids to better understand the true financial commitment before starting treatment.

Questions families commonly ask include:

• How much does growth hormone therapy cost without insurance?
• What expenses are involved beyond medication?
• Is self-pay growth hormone treatment realistic long-term?
• Does growth hormone become more expensive as a child grows?
• Are laboratory tests and bone age X-rays included?
• Can families pay cash if insurance denies HGH?
• How does cash-pay treatment compare with insurance coverage?
• How many years might a child need treatment?

Understanding the full financial picture is important because pediatric growth hormone therapy may continue for several years when treatment remains medically appropriate and growth potential remains.[1,2]

The total cost involves more than simply purchasing growth hormone.

Families may need to account for:

• Growth hormone medication
• Initial medical evaluation
• Follow-up appointments
• Laboratory testing
• Bone age imaging
• Growth monitoring
• Dose adjustments
• Injection supplies
• Pharmacy expenses

For families paying without insurance, understanding these expenses before beginning treatment can make long-term planning significantly easier.

Why Families Consider Cash-Pay Growth Hormone Therapy

Most parents initially assume health insurance will cover growth hormone therapy if a clinician recommends treatment.

In practice, coverage can be more complicated.

Insurance companies may require documentation of:

• Diagnosis
• Height and growth percentiles
• Growth velocity
• Previous growth records
• Laboratory testing
• Bone age
• Growth hormone stimulation testing when indicated
• Medical necessity
• Prior treatment
• Prescribed medication
• Continued response to therapy

Prior authorization and formulary restrictions can significantly influence access to growth hormone treatment.

Research examining U.S. growth hormone claims found that insurer restrictions and formulary strategies changed how growth hormone was paid for and that patients experienced increasing financial burden over the study period.[3]

However, an important distinction should be made:

An insurance denial is a coverage decision—it does not by itself determine whether treatment is medically appropriate or inappropriate.

Likewise, willingness to pay cash should not replace a proper medical evaluation.

Families commonly explore cash-pay treatment for several reasons.

Insurance Denial

Some children may not meet a particular insurance company's coverage criteria even when parents remain concerned about growth.

This situation may be especially relevant for diagnoses in which treatment decisions are individualized, such as idiopathic short stature.[1]

High Deductibles or Coinsurance

Having insurance does not necessarily mean treatment will be inexpensive.

Depending on the health plan, families may still face:

• Large deductibles
• Coinsurance
• Specialty pharmacy expenses
• Non-covered laboratory testing
• Out-of-network medical care

For some families, the difference between insurance-based treatment and cash-pay care may therefore be smaller than expected.

Faster Access to Care

Insurance authorization can sometimes delay medication initiation while documentation is gathered and reviewed.

Some families investigate self-pay treatment because they want to understand whether another legitimate treatment pathway is available without waiting for an insurance coverage determination.

Medical appropriateness should still be established before treatment begins.

Predictable Costs

A structured self-pay program may make budgeting easier when families understand the medical-management and medication components in advance.

Treatment Flexibility

Insurance formularies may determine which somatropin product is preferred.

A family's prescribed medication may also change if an insurer changes its formulary.

A study of U.S. pediatric GH claims documented medication brand switching associated with the changing insurance environment.[3]

What Is Growth Hormone Therapy?

HGH for children to grow taller generally refers to treatment with recombinant human growth hormone, or somatropin.

Somatropin has established pediatric uses for specific growth disorders. Depending on the product, approved indications can include growth hormone deficiency, idiopathic short stature, Turner syndrome, SHOX deficiency, and children born small for gestational age who fail to demonstrate adequate catch-up growth.[1,4]

Growth hormone influences the GH/IGF-1 pathway and contributes to:

• Linear growth
• Growth plate activity
• Bone development
• Body composition
• Protein synthesis
• Normal metabolic function

However, treatment is not appropriate for every child who is short.

Height alone does not establish growth hormone deficiency or another indication for therapy.

This is why specialists first evaluate possible explanations such as:

• growth hormone deficiency
• idiopathic short stature
• constitutional growth delay
• low IGF-1
• pituitary disorders
• Familial short stature
• Delayed puberty
• Thyroid disorders
• Nutritional problems
• Chronic disease
• Genetic or skeletal conditions

Expert guidance emphasizes that accurate longitudinal growth measurements, medical history, physical examination, growth velocity, and appropriate testing are fundamental to evaluating childhood short stature.[2]

Can You Pay Cash for Pediatric Growth Hormone?

Yes, growth hormone treatment may be paid for without insurance when it is legally prescribed and medically appropriate.

Cash-pay treatment simply means that the family is responsible for treatment expenses rather than relying primarily on an insurance company to reimburse them.

It does not mean:

• Growth hormone can be prescribed solely because a family requests it
• Medical evaluation can be skipped
• Monitoring is unnecessary
• Every short child qualifies for treatment
• Insurance denial automatically establishes a reason to prescribe HGH

The same medical considerations remain important whether treatment is paid for through insurance or out of pocket.

How Much Does Growth Hormone Cost Without Insurance?

This is one of the most searched questions surrounding pediatric growth hormone therapy.

Unfortunately, there is no single reliable national cash-pay price.

Medication expense can vary considerably according to:

• Child's weight
• Prescribed dose
• Diagnosis
• Somatropin formulation
• Manufacturer
• Pharmacy
• Package size
• Available discounts
• Treatment schedule
• Duration of therapy

Families paying completely out of pocket should generally expect growth hormone medication to represent a significant recurring expense, potentially costing several hundred dollars per month or considerably more depending on the child's prescription.

Rather than relying on a national internet average, parents should obtain a medication estimate based on the actual drug, dose, quantity, and pharmacy being considered for their child.

That provides a much more realistic estimate of cash-pay cost.

Why Published HGH Prices Can Be Misleading

Parents may encounter articles claiming that pediatric growth hormone costs a specific amount every month or every year.

These figures need context.

One frequently cited economic analysis evaluated five years of recombinant GH treatment in prepubertal boys with idiopathic short stature. Under the assumptions and medication prices used at that time, the model estimated an incremental treatment cost of approximately $99,959 per child.[5]

However, that research was published in 2006.

It should therefore be viewed as evidence that multi-year growth hormone treatment can create a substantial cumulative financial burden, not as a current cash quote for a child receiving therapy today.

Medication markets change.

So do:

• Insurance policies
• Manufacturer pricing
• Available growth hormone brands
• Biosimilar availability
• Pharmacy contracts
• Dosing requirements

For a 2026 family trying to determine what treatment will actually cost, an individualized current pharmacy quote is far more useful than an old national average.

How Much Does Cash-Pay Growth Hormone Cost Per Year?

Annual cost is determined primarily by monthly medication expense plus the cost of medical care and monitoring.

For example, a family's total expenses may include:

Medication

Growth hormone medication generally represents one of the largest recurring expenses.

Medical management

Follow-up appointments are needed to evaluate growth, response, tolerance, and treatment appropriateness.

Laboratory testing

Periodic blood testing may be recommended.

Bone age imaging

Bone age may be repeated when clinically useful to assess skeletal maturation.

Injection supplies

Depending on the product and pharmacy, supplies may or may not be included.

As a result, total annual cash-pay costs can reach many thousands of dollars, with higher-cost treatment scenarios reaching considerably more.

Families researching the long-term cost of growth hormone treatments in kids should focus on their child's expected multi-year cost rather than a generic annual average.

Why Growth Hormone Costs May Change as a Child Grows

One important factor parents sometimes overlook is dosing.

Many pediatric somatropin regimens are calculated partly according to body weight. Current FDA prescribing information for somatropin products includes weight-based pediatric dosing and recommends individualizing the dose according to the child's diagnosis and growth response.[4]

As a child gains weight, the amount of medication required may therefore change.

For example:

Smaller child → potentially less medication

Larger child → potentially more medication

This does not mean cost automatically increases every year.

Medication requirements depend on:

• Diagnosis
• Weight
• Growth response
• Prescribed dose
• Product
• Clinical circumstances

But families planning several years of cash-pay treatment should understand that the medication amount used during year one may not remain identical throughout treatment.

Does Puberty Make Growth Hormone More Expensive?

Potentially, but not simply because puberty begins.

Puberty brings major changes in:

• Body weight
• Growth velocity
• IGF-1
• Sex hormones
• Skeletal maturation

Treatment should therefore be reassessed as children progress through adolescence.

The dose may change as the child's weight or clinical needs change.

Parents should avoid assuming that a specific childhood monthly medication cost will remain identical through the teenage years.

How Long Do Children Stay on Growth Hormone?

There is no universal treatment duration.

Some children may require treatment for several years, while others may have a shorter course.

Duration depends on:

• Diagnosis
• Age when treatment begins
• Bone age
• Pubertal stage
• Growth velocity
• Response to treatment
• Remaining growth potential
• Medical goals

Current prescribing information also indicates that somatropin used for pediatric short stature should be discontinued once the epiphyses are fused.[4]

Treatment may also be stopped earlier when:

• Growth response is inadequate
• Near-final height is reached
• Clinical circumstances change
• Adverse effects require reconsideration
• Treatment is no longer considered beneficial

Therefore, parents should not automatically assume that a child will remain on HGH until a predetermined age.

Additional Cash-Pay Costs Beyond Medication

When comparing self-pay programs, medication is only part of the financial picture.

Some providers charge separately for each component of care.

Initial Pediatric Growth Evaluation

A detailed evaluation may include:

• Medical history
• Family height history
• Growth chart analysis
• Physical examination
• Pubertal assessment
• Growth velocity calculation

Laboratory Testing

Possible testing may include:

• IGF-1
• IGFBP-3
• Thyroid function
• Complete blood count
• Metabolic testing
• Celiac screening when appropriate
• Other endocrine testing based on the child's presentation

Bone Age X-Ray

Bone age can provide important information regarding skeletal maturity and remaining growth potential.

Growth Hormone Stimulation Testing

This testing is not necessary for every short child.

It may be considered when growth hormone deficiency is suspected.[2]

MRI

Pituitary imaging may be appropriate in selected children when clinical or laboratory findings suggest hypothalamic or pituitary disease.[2]

Follow-Up Visits

Children receiving GH require ongoing clinical monitoring rather than simply receiving medication refills.

Injection Supplies

Needles and other administration supplies may create an additional cost depending on the medication and pharmacy.

Families should ask which of these expenses are included and which are billed separately.

Why Proper Monitoring Is Essential

Growth hormone treatment should never be viewed as simply purchasing medication.

Appropriate care requires evaluating whether treatment is:

• Working
• Properly dosed
• Well tolerated
• Still medically appropriate

Growth Velocity

One of the most important outcomes is the child's rate of linear growth.

Children with poor growth velocity often require closer assessment.

An inadequate improvement in growth during treatment should prompt evaluation rather than automatic dose escalation.

Current somatropin prescribing information specifically notes that failure to increase growth rate, particularly during the first year, warrants assessment for adherence and other causes of poor growth.[6]

Skeletal Maturity

A bone age assessment can help determine how much skeletal growth may remain.

IGF-1

IGF-1 may be monitored as part of treatment.

However, treatment should not be managed simply by trying to achieve the highest possible IGF-1 value.

Thyroid Function

GH therapy can interact with thyroid physiology, and thyroid status may need periodic evaluation.[1,4]

Pubertal Development

Pubertal progression affects growth velocity and skeletal maturation and should be considered when interpreting treatment response.

Adverse Effects

Clinicians should also monitor for recognized complications and symptoms that warrant further evaluation.

This is why many families begin with a child height specialist consultation before discussing treatment.

What Should Be Included in a Cash-Pay Growth Hormone Program?

Families comparing programs should ask exactly what they are paying for.

A comprehensive program may include:

• Physician or clinician oversight
• Regular follow-up
• Height and weight measurements
• Growth velocity calculation
• Medication management
• Dose adjustments when appropriate
• Laboratory review
• Side-effect monitoring
• Bone age review
• Communication regarding pharmacy issues
• Long-term treatment planning

Some programs bundle these services.

Others charge separately.

A lower advertised monthly price may therefore not represent a lower total treatment cost.

HGH for Children Cash-Pay Pricing

At HGH for Children, the goal of the cash-pay model is to make treatment expenses as transparent and predictable as possible.

The overall cost generally has two major components:

Ongoing Medical Management

Medical management may include:

• Clinical oversight
• Follow-up appointments
• Growth monitoring
• Review of treatment response
• Medication management
• Dose adjustments when appropriate

Growth Hormone Medication

Medication pricing varies according to the individual child's:

• Prescription
• Body weight
• Required dose
• Medication
• Pharmacy
• Treatment duration

Families should generally expect growth hormone medication to cost several hundred dollars per month or more, depending on the child's individual prescription.

Because pharmacy prices and medication requirements can change, we do not recommend relying on a fixed medication price when estimating several years of treatment.

Families can receive more specific cost information after the child's evaluation and treatment requirements are established.

Medication pricing is approximate and subject to change. Medical-management, medication, laboratory, imaging, and other expenses should be confirmed before beginning treatment.

Why We Prefer Individualized Pricing Over a Fixed HGH Price

Publishing one exact monthly HGH price can be misleading.

Consider two children receiving treatment.

One may be:

• Younger
• Smaller
• Receiving a lower medication quantity

Another may be:

• Older
• Heavier
• Receiving a different dose or medication

Their pharmacy expenses may not be identical.

Medication pricing can also change over time.

For that reason, the most useful approach is:

Evaluate the child → determine whether treatment is appropriate → establish the prescription → obtain current medication pricing.

This gives families a more realistic estimate than promising a universal monthly price.

Cash-Pay Growth Hormone vs. Insurance

Insurance can substantially reduce treatment expenses when coverage is approved.

However, insurance and cash-pay care each have different financial considerations.

Insurance-Covered Treatment

Families may encounter:

• Copays
• Deductibles
• Coinsurance
• Prior authorizations
• Preferred medication requirements
• Specialty pharmacy requirements
• Recurring coverage reviews
• Medication brand changes

Cash-Pay Treatment

Families may experience:

• More direct understanding of costs
• Fewer insurance authorization requirements
• Greater ability to compare pharmacy options
• Potentially faster access after a treatment decision is made

However:

Cash-pay does not automatically mean less expensive.

For a family with strong insurance coverage, insurance-based treatment could be considerably less expensive.

The correct comparison is the family's actual expected annual out-of-pocket expense under each option.

What If Insurance Denies Growth Hormone?

An insurance denial can occur for many reasons.

Possible issues include:

• Diagnosis does not meet plan criteria
• Required documentation is incomplete
• Growth records are insufficient
• Testing requirements have not been met
• Prescribed product is not preferred
• Prior authorization has expired
• Treatment does not meet the insurer's medical-necessity policy

Parents should first determine why coverage was denied.

Depending on the circumstances, options may include:

• Supplying additional records
• Appealing the decision
• Trying the preferred medication
• Requesting clinician review
• Investigating manufacturer assistance
• Comparing legitimate cash-pay options

An insurance denial should not automatically lead to treatment.

The underlying medical indication should still be established independently.

Does Paying Cash Mean You Can Skip Growth Hormone Testing?

No.

The necessary evaluation depends on the child rather than the payment method.

A cash-pay patient should receive the same thoughtful evaluation of growth as a patient using insurance.

Expert recommendations for evaluating short stature emphasize careful analysis of the child's growth history and targeted testing based on the clinical presentation.[2]

Depending on the child, evaluation could include:

• Growth records
• Growth velocity
• Bone age
• IGF-1
• IGFBP-3
• Thyroid testing
• Screening for systemic illness
• Genetic assessment
• Growth hormone stimulation testing when appropriate

Paying cash changes who pays the bill.

It should not change the medical standard used to determine whether treatment makes sense.

Is Cash-Pay HGH Worth It?

There is no universal answer.

The value of treatment depends heavily on the child's diagnosis and likely benefit.

Diagnosis

Children with established growth hormone deficiency have a different medical rationale for GH replacement than children with other forms of short stature.[1]

Growth Potential

A bone age assessment can help estimate skeletal maturity and remaining growth opportunity.

Expected Outcomes

Parents often ask:

How tall will my child be?

No clinician can guarantee final adult height.

Treatment response varies between children, and predicted adult height is itself an estimate.

Treatment Duration

A modest monthly expense becomes significant when multiplied by several years.

Family Financial Situation

A treatment plan that is financially manageable for one family may be unrealistic for another.

Long-term affordability matters because interrupting therapy for financial reasons may affect the treatment plan.

Comparing the Cost and Benefit of Different Growth Options

Parents frequently research alternatives before committing to several years of treatment.

Useful comparisons include:

• cost comparison sermorelin vs HGH in children
• cost vs benefit of growth hormone therapy in a child
• chearper alternatives to HGH for children

However, cost should not be the only basis for choosing therapy.

Different treatments have different mechanisms, levels of supporting evidence, approved uses, and expected outcomes.

The least expensive option is not necessarily the most appropriate option.

Likewise, the most expensive treatment is not automatically the most effective.

The first question should always be:

What is causing this child's growth pattern?

How Families Can Reduce the Financial Burden of Growth Hormone Treatment

Families may be able to reduce expenses by investigating several legitimate options.

Compare Insurance Benefits

Understand the deductible, coinsurance, medication formulary, and specialty pharmacy requirement.

Ask About Preferred Growth Hormone Products

A different FDA-approved somatropin product may have better insurance coverage under a particular plan.

Compare Pharmacy Pricing

Cash pricing may differ between pharmacies.

Investigate Manufacturer Programs

Eligibility varies, but some manufacturers offer assistance or copay programs.

Understand What the Medical Program Includes

Bundled medical management may be easier to budget than paying separately for frequent visits.

Avoid Unnecessary Testing

Testing should be driven by clinical need rather than automatically repeating large panels.

Reassess Whether Treatment Is Working

Continuing an expensive medication without adequate benefit does not make financial or medical sense.

Questions to Ask a Cash-Pay Growth Hormone Clinic

Before committing to treatment, parents may want answers to the following:

• What is my child's diagnosis?
• Why is growth hormone being recommended?
• Does my child meet accepted treatment criteria?
• What is my child's growth velocity?
• What is my child's bone age?
• How much growth potential remains?
• What medication will be prescribed?
• What is the current pharmacy price?
• Could medication requirements increase as my child gains weight?
• What services are included in the medical-management fee?
• Are laboratory tests included?
• Is bone age included?
• How frequently are follow-ups required?
• How will treatment response be measured?
• What happens if my child does not respond?
• How many years might treatment continue?
• What is the realistic estimated annual cost?
• Are there additional expenses not included in the quoted price?

A clinic should be able to clearly explain both the medical rationale and the financial structure before a family begins long-term treatment.

The Bottom Line

The cost of cash-pay growth hormone therapy for kids can vary substantially depending on:

• Medication
• Dose
• Body weight
• Diagnosis
• Pharmacy
• Medical monitoring
• Testing
• Treatment duration

Published research demonstrates that long-term growth hormone treatment can represent a substantial financial commitment, while U.S. claims research also shows that insurance policies and formulary restrictions can meaningfully affect what families ultimately pay.[3,5]

For that reason, families should be cautious about websites advertising one universal monthly or annual HGH price.

A more useful approach is to determine:

Why is my child growing slowly?

Is growth hormone actually appropriate?

How much growth potential remains?

What medication and dose would be required?

What is the current pharmacy cost?

What additional monitoring expenses should we expect?

How many years might treatment continue?

Whether a child has growth hormone deficiency, idiopathic short stature, constitutional growth delay, low IGF-1, a pituitary disorder, or another cause of slow growth, the appropriate treatment plan begins with the correct diagnosis.

Cash-pay treatment can change how care is financed, but it should never replace appropriate pediatric growth evaluation, medical supervision, or evidence-informed treatment decisions.

Medically Reviewed By

Dr. Devin Stone, ND

Dr. Devin Stone is a Doctor of Naturopathic Medicine and founder of HGHforChildren.com. His clinical focus includes pediatric growth evaluation, short stature assessment, delayed bone age, constitutional growth delay, IGF-1 interpretation, growth hormone signaling, and evidence-informed treatment planning for children and adolescents with growth concerns.

Through HGHforChildren.com, Dr. Stone helps families understand childhood growth patterns, growth velocity, bone age, laboratory evaluation, treatment options, and the potential financial considerations associated with pediatric growth programs.

Medical References & Cost Evidence

1. Grimberg A, DiVall SA, Polychronakos C, et al. Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency. Hormone Research in Paediatrics. 2016;86(6):361-397. doi:10.1159/000452150. PMID: 27884013.
Pediatric Endocrine Society guideline addressing diagnosis, treatment decisions, individualized GH therapy, treatment response, and monitoring in children with GHD, ISS, and primary IGF-I deficiency.

2. Collett-Solberg PF, Ambler G, Backeljauw PF, et al. Diagnosis, Genetics, and Therapy of Short Stature in Children: A Growth Hormone Research Society International Perspective. Hormone Research in Paediatrics. 2019;92(1):1-14. doi:10.1159/000502231. PMID: 31514194.
International expert guidance covering evaluation of pediatric short stature, growth velocity, bone age, endocrine testing, genetic evaluation, and appropriate treatment considerations.

3. Grimberg A, Kanter GP. US Growth Hormone Use in the Idiopathic Short Stature Era: Trends in Insurer Payments and Patient Financial Burden. Journal of the Endocrine Society. 2019;3(11):2023-2031. doi:10.1210/js.2019-00246. PMID: 31637343.
Analysis of U.S. commercial insurance claims demonstrating changes in GH expenditures, insurer payments, patient financial burden, formulary restrictions, and medication brand switching.

4. U.S. National Library of Medicine. DailyMed. HUMATROPE (somatropin) Prescribing Information.
Current FDA labeling describes pediatric indications, weight-based dosing ranges, individualized dosing according to growth response, important safety information, and contraindication in pediatric patients with closed epiphyses.

5. Lee JM, Davis MM, Clark SJ, Hofer TP, Kemper AR. Estimated Cost-Effectiveness of Growth Hormone Therapy for Idiopathic Short Stature. Archives of Pediatrics & Adolescent Medicine. 2006;160(3):263-269. doi:10.1001/archpedi.160.3.263. PMID: 16520445.
A five-year economic model of GH treatment for idiopathic short stature demonstrating the substantial cumulative cost of long-term therapy and the influence of growth response on cost-effectiveness. Historical cost figures should not be interpreted as current medication prices.

6. U.S. National Library of Medicine. DailyMed. OMNITROPE (somatropin) Prescribing Information.
Current prescribing information supports individualized pediatric dosing, monitoring of growth response, reassessment of inadequate first-year response, and discontinuation of short-stature therapy after epiphyseal fusion.